New antibody drug shows early promise for Hard-to-Treat blood cancers
NCT ID NCT05822843
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a new drug called ESG206 in 13 adults with B-cell blood cancers that had not responded to standard treatments. ESG206 is an antibody designed to attach to a protein called BAFFR on cancer cells and help the immune system attack them. The main goals were to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ESG206 (an antibody that targets BAFFR on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with B-cell blood cancers who have run out of standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 13 participants, so it is mainly checking safety and dosing. The drug may not shrink tumors or may cause side effects, and much larger studies are needed to know if it really helps.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China